CL2012000062A1 - Uso de interferon beta 1a y beta 1b para tratar la forma relapsante-remitente de la esclerosis multiple. - Google Patents

Uso de interferon beta 1a y beta 1b para tratar la forma relapsante-remitente de la esclerosis multiple.

Info

Publication number
CL2012000062A1
CL2012000062A1 CL2012000062A CL2012000062A CL2012000062A1 CL 2012000062 A1 CL2012000062 A1 CL 2012000062A1 CL 2012000062 A CL2012000062 A CL 2012000062A CL 2012000062 A CL2012000062 A CL 2012000062A CL 2012000062 A1 CL2012000062 A1 CL 2012000062A1
Authority
CL
Chile
Prior art keywords
beta
multiple sclerosis
remitting form
treat relapsing
interferon
Prior art date
Application number
CL2012000062A
Other languages
English (en)
Inventor
William Byrnes
Patrice Douillet
Gerald Frangin
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41283539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of CL2012000062A1 publication Critical patent/CL2012000062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de interferon beta 1A y beta 1B para tratar la forma relapsante-remitente de la esclerosis múltiple.
CL2012000062A 2009-07-10 2012-01-09 Uso de interferon beta 1a y beta 1b para tratar la forma relapsante-remitente de la esclerosis multiple. CL2012000062A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09305669A EP2277515A1 (en) 2009-07-10 2009-07-10 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
US22534209P 2009-07-14 2009-07-14
US28614809P 2009-12-14 2009-12-14
US35095710P 2010-06-03 2010-06-03

Publications (1)

Publication Number Publication Date
CL2012000062A1 true CL2012000062A1 (es) 2012-10-05

Family

ID=41283539

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000062A CL2012000062A1 (es) 2009-07-10 2012-01-09 Uso de interferon beta 1a y beta 1b para tratar la forma relapsante-remitente de la esclerosis multiple.

Country Status (20)

Country Link
US (2) US20120107277A1 (es)
EP (2) EP2277515A1 (es)
JP (1) JP2012532881A (es)
KR (1) KR20120050976A (es)
CN (1) CN102470116A (es)
AR (1) AR077460A1 (es)
AU (1) AU2010271467A1 (es)
BR (1) BR112012000490A2 (es)
CA (1) CA2767711A1 (es)
CL (1) CL2012000062A1 (es)
CO (1) CO6491023A2 (es)
IL (1) IL217434A0 (es)
MA (1) MA33515B1 (es)
MX (1) MX2012000458A (es)
RU (1) RU2012104666A (es)
SG (1) SG177544A1 (es)
TW (1) TW201106945A (es)
UY (1) UY32781A (es)
WO (1) WO2011005907A1 (es)
ZA (1) ZA201108340B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP1935416A3 (en) * 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
CN101043883A (zh) * 2004-10-19 2007-09-26 安万特药物公司 (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途

Also Published As

Publication number Publication date
SG177544A1 (en) 2012-03-29
UY32781A (es) 2011-02-28
CA2767711A1 (en) 2011-01-13
CO6491023A2 (es) 2012-07-31
AU2010271467A1 (en) 2012-02-02
IL217434A0 (en) 2012-02-29
TW201106945A (en) 2011-03-01
AR077460A1 (es) 2011-08-31
JP2012532881A (ja) 2012-12-20
WO2011005907A1 (en) 2011-01-13
EP2451449A1 (en) 2012-05-16
BR112012000490A2 (pt) 2016-02-16
EP2451449B1 (en) 2014-05-07
EP2277515A1 (en) 2011-01-26
KR20120050976A (ko) 2012-05-21
ZA201108340B (en) 2012-07-25
RU2012104666A (ru) 2013-08-20
MX2012000458A (es) 2012-01-27
CN102470116A (zh) 2012-05-23
US20130156735A1 (en) 2013-06-20
US20120107277A1 (en) 2012-05-03
MA33515B1 (fr) 2012-08-01

Similar Documents

Publication Publication Date Title
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
UY34395A (es) ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?.
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
ECSP13012844A (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
AU335765S (en) Tile spacer
CO6870005A2 (es) Composición anti-cgrp y uso de las mismas
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
CA141065S (en) Dual c clip
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
UY33754A (es) Monobactamas
BR112013027716A2 (pt) gavetas rápidas com rolos e rampa
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
BR112014002092A2 (pt) tratamento de esclerose múltipla com combinação de laquinimod e interferon-beta
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2014003059A1 (es) Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose.
CA141066S (en) Dual c clip
UY34315A (es) ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ?
BR112014007150A2 (pt) artigos abrasivos de redução de ruído
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
CL2014000269A1 (es) Uso de interleucina 7 (il-7) para tratar hepatitis c en combinacion o con posterioridad a un agente antiviral o una combinacion de agentes antivirales.
RS54412B1 (en) COMPOSITION OF BEE HONEY AND L-ALANYL-L-GLUTAMINE